VivaBioCell. Delivering next-generation manufacturing solutions for sustainable cell therapies

Benefits

cGMP-compliance, Scale Out and Cost Efficiency. Enabling the transition from your manual protocol to an automated process. Learn more ⟩

Technology

Empowering your ATMP manufacturing with Automation, Flexibility, Integrated Imaging and Remote Monitoring. Learn more ⟩

NANT XL System

The evolution of automated cell expansion systems for mid- up to large-scale batch sizes. Maximum flexibility in cell expansion for clinical and commercial Advanced Therapies manufacturing needs. Learn more ⟩

NANT XL System

NANT 001 System

Seamless transition from R&D to clinical and commercial manufacturing. Automated cell expansion for small- to mid-scale batches, ideal for autologous and redistributed scale-out manufacturing. Learn more ⟩

NANT 001 System

NANT Maestro

Your cell factory dashboard. A range of Apps to help you monitor and manage all your NANT Systems from one easy, centralized and convenient interface. Learn more ⟩

NANT Maestro

Latest News

VivaBioCell at the "European Orthopaedic Research Society" Conference
VivaBioCell will attend next EORS Annual Meeting in Rome (15-17 September 2021) and showcase novel innovative technologies revolutionizing the approach to traditional orthopedics. Read more ⟩

ImmunityBio + NANT 001 Bioreactor

FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors
ImmunityBio, Inc. announced it has received FDA authorization to conduct a Phase 1 study to evaluate the safety and preliminary efficacy of its m-ceNK platform in subjects with locally advanced or metastatic solid tumors. Read more ⟩

Camp 2020

VivaBioCell is now a partner of the Centre for Advanced Medical Products (CAMP) - Sweden
We're very proud to be the first international partner of the Centre for Advanced Medical Products (CAMP), making our technology available to develop new innovative therapeutic applications in Sweden. Read more ⟩